Journalists working on stories related to high-risk pregnancies or the Society for Maternal-Fetal Medicine can contact Greg Phillips, Director of Communications, at press@smfm.org for referrals to MFM experts and to request additional information. The press office is open Monday through Friday from 9:00 AM to 5:00 PM ET.
Prepregnancy counseling, assembling multidisciplinary care teams, and referring to centers with expertise are critical in managing pregnant patients with heart failure to optimize maternal and newborn health outcomes, according to new guidance issued by SMFM. Continue Reading
*This tip was originally published in April 2025 and has since been updated to reflect recent changes. The Society for Maternal-Fetal Medicine (SMFM) Coding Committee; Brad Hart, MBA, MS, CPC, CPMA, COBGC; Stephen Bacak, DO, FACOG; Steve Rad MD, FACOG, SMFM Coding Committee Chair, Trisha... Continue Reading
By: Adam K. Lewkowitz, MD, MPHS, and Emily S. Miller, MD, MPH On July 21, 2025, the Food and Drug Administration (FDA) convened a roundtable panelist discussion on the use of selective serotonin reuptake inhibitors (SSRIs), a class of antidepressant medication, in pregnancy. The FDA... Continue Reading
The Society for Maternal-Fetal Medicine (SMFM) Coding Committee; Robert Rossi, MD Katherine Kohari, MD Barbra Fisher, MD, PhD and Betzaida Martinez CPC, CPMA, COBGC, CPPM Background Multiple societies (AIUM, SMFM, ACOG, ACOOG, SDMS, SFP, and FHS) recommend performing a detailed fetal... Continue Reading
By Brian K. Iriye, MD; Vanita D. Jain, MD; and Anthony C. Sciscione, DO What is DFTU and Why Is It Important? The Detailed First-Trimester Ultrasound (DFTU) is a high-resolution scan performed between weeks 12 and 13 of pregnancy to detect fetal structural anomalies.1 It is indicated for... Continue Reading
As experts in high-risk pregnancies, the Society for Maternal-Fetal Medicine (SMFM) and its members are alarmed by the unsubstantiated and inaccurate claims made by FDA panelists concerning maternal depression and the use of SSRI antidepressants during pregnancy. Continue Reading
More than 30 organizations representing millions of patients with serious health conditions and thousands of medical professionals are applauding the protection of access to lifesaving preventive care without patient cost sharing. Continue Reading
By Kristen A. Cagino, MD As physicians, we recognize that medical practice is built on a foundation of research. Discovering new therapies, navigating a global pandemic, and identifying the safest, evidence-based management strategy for complex conditions all rely on rigorous, well-designed... Continue Reading
Our organizations maintain that mifepristone is a safe, effective, and integral part of the medical care that our members provide to their patients. Continue Reading
Media Contact:Karen Addis, APRkaren@addispr.com+1 (301) 787-2394 One of the Largest Studies on Preterm Birth Finds a Maternal Biomarker Test Significantly Reduces Neonatal Morbidities and Improves Neonatal Outcomes Denver, Colo. ― Preterm birth ― defined as delivery before the 37th week of... Continue Reading
FOR IMMEDIATE RELEASE:Jan. 30, 2025 Media Contact:Karen Addis, APRkaren@addispr.com+1 (301) 787-2394 New Study Finds Increased Maternal Complications with Previable Premature Rupture of Membranes Denver, Colo. ― Previable premature rupture of membranes (PROM) is when the amniotic sac, the... Continue Reading
There are currently three CPT codes specific to continuous glucose monitoring (CGM) services. The first two codes are for the hook-up, calibration, sensor placement, patient training, and initial printout. The codes are differentiated by whether the patient provided the equipment... Continue Reading
